fluorexon has been researched along with Malignant Melanoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Caramalho, I; Faroudi, M; Müller, S; Padovan, E; Valitutti, S | 1 |
Berger, W; Elbling, L; Hauptmann, E; Kokoschka, EM; Micksche, M; Vetterlein, M | 1 |
2 other study(ies) available for fluorexon and Malignant Melanoma
Article | Year |
---|---|
Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation.
Topics: Apoptosis; Cell Proliferation; Cell Separation; Cytotoxicity, Immunologic; Flow Cytometry; Fluoresceins; Immunotherapy; Ligands; Major Histocompatibility Complex; MART-1 Antigen; Melanoma; Microscopy, Confocal; Peptides; T-Lymphocytes, Cytotoxic; Time Factors | 2009 |
Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzbromarone; Blotting, Northern; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Ethylmaleimide; Etoposide; Female; Fluoresceins; Humans; Male; Melanoma; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; RNA, Messenger; Tumor Cells, Cultured; Uricosuric Agents; Vinblastine | 1997 |